News & Events
Keyword Search
 
2017 | 2016
DateTitle 
09/07/17Kelly Huang, Ph.D., Joins Obalon Therapeutics, Inc. Executive Team
SAN DIEGO, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company, announced today that Kelly Huang, Ph.D., has joined as its Chief Operating Officer.  In this new role, Dr. Huang will be responsible for the key commercial functions of sales, marketing, operations, and quality assurance.  “As we continue to expand our executive team, Dr. Huang’s technical expertise, coupled with his experience leading successful busines... 
08/02/17Obalon Announces Second Quarter 2017 Financial Results
SAN DIEGO, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its unaudited financial results as of and for the second quarter ended June 30, 2017.  Second Quarter 2017 highlights: Revenue grew 33% sequentially over Q1-17 to $2.0 million Gross margin improved to 50% First c... 
07/31/17Obalon Announces Upcoming Conference Presentation
SAN DIEGO, July 31, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that management will present an update on Obalon at the following upcoming investor conference: Andy Rasdal, Chief Executive Officer and Bill Plovanic, Chief Financial Officer of Obalon will present an update on the com... 
07/27/17Obalon Schedules Second Quarter 2017 Financial Results Conference Call for August 2, 2017 at 8:30 a.m. Eastern Time
SAN DIEGO, July 27, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to release its second quarter 2017 financial results before the market opens on Wednesday, August 2, 2017. The company will hold a conference call and simultaneous webcast at 8:30 AM, Eastern Time (5:30 AM Pacifi... 
05/22/17Obalon Therapeutics, Inc. to Present at UBS Global Healthcare Conference
SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Andy Rasdal, Chief Executive Officer of Obalon, and William Plovanic, Chief Financial Officer of Obalon, will present at the following investor conference: UBS Global Healthcare Conference Tuesday, May 23, 2017, Pr... 
05/11/17Obalon Receives Regulatory Approvals to Commercialize in Select Middle East Markets
SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced regulatory approvals in select international markets.  Obalon has received notification that it has obtained the necessary regulatory approvals in select Middle East markets to commercialize the Obalon six-month balloon and ... 
05/10/17Obalon Announces First Quarter 2017 Financial Results
SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2017.  The Company reported total revenues of $1.5 million for the first quarter of 2017, compared to $1.1 million for the first quarter of 2016. All revenues in th... 
05/05/17Obalon Announces First Quarter 2017 Financial Results Conference Call
SAN DIEGO, May 05, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, will announce its financial results for the first quarter ending March 31, 2017, before the market opens on Wednesday, May 10, 2017. The company will hold a conference call and simultaneous webcast at 8:30 AM Eastern Time (5:30 AM Pacific T... 
04/28/17Obalon Balloon System to be Included in Two Presentations at the Aesthetic Meeting 2017
The Aesthetic Meeting is the Largest Annual Meeting of Aesthetic Plastic Surgeons in the World SAN DIEGO, April 28, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced that the Obalon Balloon System was featured this afternoon in the “Premier Global Hot Topics” panel at the Aesthetic Meeting 2017, the ... 
03/15/17David Moatazedi Joins Obalon Therapeutics, Inc. Board of Directors
SAN DIEGO, March 15, 2017 (GLOBE NEWSWIRE) --  Obalon Therapeutics Inc. (NASDAQ:OBLN), a vertically integrated medical technology company, announced today that David Moatazedi, Senior Vice President, US Medical Aesthetics for Allergan plc has been appointed to its board of directors.  Mr. Moatazedi is the second addition to the Obalon board of directors in 2017, as Obalon continues its launch of the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intragastric bal... 
02/23/17Obalon Therapeutics, Inc. Announces Fourth Quarter and Full Year 2016 Financial Results
SAN DIEGO, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2016. “2016 was a transformative year for Obalon. We submitted our PMA filing for approval of the Obalon balloon system in January 2016 and recei... 
02/15/17Obalon Therapeutics Inc Announces Fourth Quarter and Year End 2016 Financial Results Conference Call
SAN DIEGO, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, will announce its financial results for the fourth quarter and full year ending December 31, 2016, before the market opens on Thursday, February 23, 2017. The company will hold a conference call and simultaneous webcast at 8:30 AM Eastern ... 
01/19/17Obalon Therapeutics, Inc. to Ring The Nasdaq Stock Market Closing Bell
SAN DIEGO, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics Inc. (NASDAQ:OBLN), a vertically integrated medical technology company, announced today that they will be ringing the Nasdaq Stock Market closing bell, to recognize the recent launch of the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss.  Physicians began treating patients with the Obalon Balloon System last week. “On September 8th, Obalon received approval f... 
01/17/17Jonah Shacknai Joins Obalon Therapeutics, Inc. Board of Directors
Mr. Shacknai Joins Raymond Dittamore and Les Howe As Newest Additions to Board SAN DIEGO, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics Inc. (NASDAQ:OBLN), a vertically integrated medical technology company, announced today that Jonah Shacknai, Executive Chairman of DermaForce and former Chairman and Chief Executive Officer of Medicis has been elected to its board of directors.  Mr. Shacknai joins Raymond Dittamore and Les Howe as the latest members of Obalon Therapeutic’s board of di... 
01/13/17Obalon Announces Initial Commercial Patient Placements of the First and Only Swallowable, FDA-Approved Balloon System for Weight Loss
SAN DIEGO, Calif., Jan. 13, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics Inc. (NASDAQ:OBLN), a vertically integrated medical technology company, announced that it has begun U.S. commercial shipments of the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intragastric balloon system for weight loss. The first patients have been treated by physicians in key metropolitan markets across the United States. Candidates for Obalon are adults 30 to 100 pounds overweight an... 
Upcoming Events
There are currently no events scheduled.
Past Events
DateTitle
08/02/17 8:30 a.m. ET
Obalon Second Quarter 2017 Conference Call
05/10/17 8:30 a.m. ET
Obalon First Quarter 2017 Conference Call
02/23/17 8:30 a.m. ET
Obalon Fourth Quarter 2016 Conference Call
11/11/16 5:00 a.m. PT
Obalon Third Quarter 2016 Conference Call
IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click on Safety Information and Patient Labeling